| Code | CSB-RA012928MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to JAB-BX300, specifically targeting Leukemia Inhibitory Factor (LIF), a pleiotropic cytokine belonging to the interleukin-6 (IL-6) family. LIF plays critical roles in multiple biological processes including stem cell maintenance, embryonic development, neuronal differentiation, and inflammatory responses. Through binding to the LIF receptor (LIFR) and glycoprotein 130 (gp130), LIF activates downstream JAK-STAT, MAPK, and PI3K signaling pathways. Dysregulated LIF expression has been implicated in various pathological conditions, including cancer progression, metastasis, chemotherapy resistance, and inflammatory diseases. Elevated LIF levels are particularly associated with poor prognosis in several malignancies and contribute to tumor microenvironment modulation.
The reference antibody JAB-BX300 has been utilized in research investigating LIF-mediated signaling mechanisms and its role in disease pathogenesis. This biosimilar provides researchers with a reliable tool for studying LIF function in cellular differentiation, cancer biology, immunology, and developmental biology research. It enables investigation of LIF blockade as a potential therapeutic strategy and facilitates mechanistic studies of cytokine signaling networks.
There are currently no reviews for this product.